Overview

Artichoke extract is obtained from the leaves of Cynara scolymus, a thistle-like plant cultivated throughout the Mediterranean region. The primary bioactive constituents include cynarin, chlorogenic acid, and luteolin, which collectively contribute to the extract's antioxidant and choleretic effects. Historically, artichoke has been used in traditional European medicine to support liver function and digestion.

Clinical studies have investigated artichoke extract for its ability to reduce total cholesterol and LDL cholesterol levels, with several randomized controlled trials demonstrating modest but statistically significant lipid-lowering effects. The mechanism is believed to involve inhibition of HMG-CoA reductase and enhanced bile acid secretion, which promotes cholesterol excretion. Additional research has explored its potential for alleviating symptoms of functional dyspepsia and irritable bowel syndrome.

Artichoke extract is generally well-tolerated, with most adverse effects being mild gastrointestinal complaints. Standardized extracts typically provide defined concentrations of cynarin or caffeoylquinic acids. Individuals with known allergies to plants in the Asteraceae family should exercise caution, and those with bile duct obstruction are typically advised to avoid use.

Mechanism of Action

Primary Bioactive Constituents

Artichoke extract (Cynara scolymus) contains bioactive compounds including cynarin (1,3-dicaffeoylquinic acid), chlorogenic acid, luteolin, and luteolin-7-O-glucoside. These polyphenolic compounds act synergistically across hepatobiliary, lipid metabolism, and antioxidant pathways (PMID: 17965065).

Choleretic & Hepatoprotective Mechanisms

Cynarin and chlorogenic acid stimulate bile acid synthesis and secretion by activating the farnesoid X receptor (FXR) and upregulating cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid production. Increased bile flow enhances cholesterol elimination and improves fat digestion. Luteolin provides hepatoprotection by scavenging ROS and inhibiting lipid peroxidation in hepatocytes (PMID: 12587690).

Lipid-Lowering Pathway — HMG-CoA Reductase Inhibition

Artichoke extract inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway for cholesterol biosynthesis — the same target as statin drugs. Luteolin is the primary active compound responsible for this effect. Additionally, the extract reduces LDL oxidation by scavenging peroxyl radicals and chelating copper ions that catalyze LDL oxidative modification (PMID: 18262715).

AMPK Activation & Metabolic Effects

Chlorogenic acid activates AMP-activated protein kinase (AMPK) in hepatocytes and skeletal muscle, suppressing fatty acid synthesis (via ACC inhibition) and promoting beta-oxidation. This pathway reduces hepatic lipogenesis and improves insulin sensitivity, relevant to non-alcoholic fatty liver disease (NAFLD) management (PMID: 23439573).

Digestive & Gastroprotective Effects

Artichoke extract promotes gastric motility through acetylcholine-mediated stimulation of smooth muscle and increases pancreatic enzyme secretion. Its antispasmodic effect on the GI tract is mediated by luteolin's inhibition of phosphodiesterase-4 (PDE4), reducing cAMP degradation in smooth muscle cells and relieving dyspepsia symptoms.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Artichoke Extract (Cynara scolymus / Cynara cardunculus)

Common Side Effects

• Gastrointestinal effects: flatulence, bloating, mild diarrhea (most common, reported in 5-10% of clinical trial participants)
• Increased appetite (related to choleretic/bile-stimulating activity)
• Allergic skin reactions: contact dermatitis, urticaria (particularly in individuals with Asteraceae/Compositae family sensitivities)
• Mild hunger or increased bowel frequency due to enhanced bile flow
• Transient mild headache

Serious Adverse Effects

• Bile duct obstruction worsening: Artichoke extract is a potent choleretic (increases bile production). In patients with existing gallstones or bile duct obstruction, enhanced bile flow may precipitate biliary colic or acute cholecystitis
• Anaphylaxis: Documented in individuals with Compositae family allergies (chamomile, ragweed, chrysanthemums, marigolds)
• Hepatotoxicity: Extremely rare; paradoxically, artichoke extract is generally hepatoprotective, but isolated case reports exist with concentrated extracts
• Severe allergic contact dermatitis with occupational exposure (artichoke handlers)
• Hypoglycemia when combined with antidiabetic medications (artichoke has modest glucose-lowering properties)

Contraindications

• Known allergy to artichoke or other Asteraceae/Compositae family plants (ragweed, chrysanthemums, marigolds, daisies)
• Bile duct obstruction (choledocholithiasis)
• Active gallstones (cholelithiasis) unless under medical supervision
• Acute cholecystitis or cholangitis
• Severe hepatic failure
• Known hypersensitivity to cynarin, luteolin, or chlorogenic acid

Drug Interactions

• Statins (atorvastatin, rosuvastatin): Artichoke extract may have additive lipid-lowering effects; monitor for myopathy symptoms. CYP3A4 inhibition by artichoke flavonoids may increase statin levels
• Antidiabetic medications: Additive blood glucose-lowering effect; monitor for hypoglycemia
• Anticoagulants (warfarin): Vitamin K content in artichoke may affect INR; generally modest effect but monitor
• Bile acid sequestrants (cholestyramine): Pharmacodynamic interaction via bile metabolism; may alter efficacy of either agent
• CYP3A4 substrates: Artichoke flavonoids (luteolin) inhibit CYP3A4 in vitro; clinical significance at standard supplement doses likely minimal but caution with narrow therapeutic index drugs
• Antihypertensives: Modest ACE-inhibitory activity reported; potential additive hypotension
• Iron supplements: Enhanced bile flow may improve or alter iron absorption

Population-Specific Considerations

• Pregnancy: Insufficient human safety data during pregnancy, though artichoke has long traditional use as food. Animal reproductive studies have not shown teratogenicity. European Medicines Agency (EMA) advises against use during pregnancy due to lack of formal safety studies. Avoid concentrated extracts during pregnancy; culinary use likely safe
• Pediatric: Limited formal study in children. Generally considered safe as a food component. Concentrated supplements not recommended for children under 12 due to lack of safety data. No established pediatric dosing for therapeutic use
• Elderly: Well tolerated in older adults in clinical trials (up to 640 mg/day of standardized extract). Beneficial effects on dyslipidemia and digestive complaints in elderly well-documented. Monitor for drug interactions. Ensure adequate gallbladder function before use

Pharmacokinetic Profile